International Paper
IP
$30.36
-2.41%
International Paper is one of the world's largest packaging and paper producers, manufacturing corrugated containers, containerboard, and cellulose fibers across North America and, following its acquisition of DS Smith, a substantially expanded European footprint; it serves industrial, consumer products, and manufacturing end markets. The company is a scale incumbent rather than a disruptor, controlling roughly one-third of the North American corrugated packaging market and functioning as a bellwether for box demand and industrial activity. The current investor debate centers on the DS Smith integration and a reported potential sale of the European business, which bulls frame as a value-unlocking portfolio simplification while bears point to persistent North American demand weakness and a deeply loss-making third quarter driven by large non-cash charges. Management's cost-cutting and market-share gains are being weighed against a soft packaging demand cycle, a leveraged balance sheet, and a dividend that is currently not covered by earnings, making this a contested turnaround-and-integration story rather than a clean growth narrative.…
IP
International Paper
$30.36
Related headlines
Investment Opinion: Should I buy IP Today?
Rating: Hold with a speculative value tilt. The core thesis is that International Paper is a deeply discounted, charge-distorted turnaround where the market is pricing structural deterioration (0.84x PS, 1.40x P/B, 11.08x forward PE on $3.86 consensus EPS) while 9 of 10 analysts rate it Buy with a $42.30 average target implying 39.3% upside from $30.36. The recommendation is not Buy because the near-term evidence — $75 million trailing FCF against $980 million of annualized dividends, -$267 million Q3 FCF, and a stock 4.8% off its $29.26 low — argues for waiting for confirmation rather than catching the falling knife.
Supporting evidence for the constructive side: the entire sell-side range ($35.00 low to $51.00 high) sits above the current price, with even the low target 15.3% higher; the Q3 net loss of $1.126 billion is driven by $2.489 billion of other expenses while gross margin held at 31.21% ($1.934 billion gross profit) and Q1 2026 was profitable at $60 million; PS of 0.84x and P/B of 1.40x sit far below the company's own recent band (PS 2.83x in Q3 2026, 4.08x in Q4 2024; P/B 2.29x at year-end 2024); and a potential EMEA divestiture ($1.550 billion of quarterly revenue from DS Smith) could de-lever a 0.73 debt-to-equity balance sheet and support the 4.70% yield. Against that, revenue is flat at -0.4% YoY, trailing net margin is -14.12%, ROE is -23.71%, and the payout ratio of -27.8% means the dividend is not earned.
Three risks could invalidate the thesis: (1) Q4 results confirming that Q3 charges were not fully one-time, which would force the 9 Buy ratings and $42.30 target to be cut and remove the main price support; (2) the European sale stalling or pricing below expectations, leaving the balance sheet levered at 0.73 D/E with negative FCF; and (3) continued box-demand weakness keeping revenue near $6.0-6.2 billion per quarter. This Hold would upgrade to Buy if free cash flow turns positive for two consecutive quarters or a European sale is announced at an attractive multiple, and would downgrade to Sell on a decisive break below $29.26 or a dividend cut. On valuation, the stock is undervalued relative to its own history and to mid-teens packaging peer multiples, but that discount is arguably deserved until cash generation is restored — fairly valued to modestly cheap on normalized earnings, expensive on trailing cash flow.
Sign up to view all
IP 12-Month Price Forecast
The setup is a classic deep-value-versus-deterioration debate: the stock trades at 0.84x PS and 11.08x forward PE on $3.86 consensus EPS, far below its own historical multiples and mid-teens packaging peers, while the entire sell-side range of $35.00-$51.00 sits above the $30.36 price. The bull case rests on the Q3 loss being charge-driven rather than operational — gross margin held at 31.21% and Q1 2026 was profitable at $60 million — plus a European divestiture that could de-lever a 0.73 debt-to-equity balance sheet. The bear case is that $75 million of trailing FCF cannot cover $980 million of dividends, revenue is flat at -0.4% YoY, and the stock sits just 4.8% above its $29.26 low after a -40.27% max drawdown. I would upgrade to bullish on two consecutive quarters of positive free cash flow or an announced European sale at an attractive multiple, and downgrade to bearish on a decisive break below $29.26, a dividend cut, or Q4 confirming recurring charges. Until cash generation is restored, the discount is a warning rather than a clean opportunity, which is why the stance is neutral with medium confidence.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Paper's 12-month outlook, with a consensus price target around $42.30 and implied upside of +39.3% versus the current price.
Average Target
$42.30
11 analysts
Implied Upside
+39.3%
vs. current price
Analyst Count
11
covering this stock
Price Range
$35 - $51
Analyst target range
Coverage is solid for a large-cap basic materials name, with 10 analysts and a distribution of 9 Buy, 2 Hold, and 0 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.73 (where 1.0 is a strong buy). The average target price of $42.30 implies roughly 39.3% upside from the current $30.36, a wide gap that signals analysts are valuing the company on normalized earnings and asset value rather than the depressed trailing results. The bullish consensus stands in stark contrast to the stock's -24.57% YTD performance, suggesting either a significant disconnect between sell-side models and market pricing or that the market is discounting the recovery assumptions embedded in those targets.
The target range of $35.00 to $51.00 is wide, spanning 45.7% between low and high, which signals meaningful uncertainty about the European asset sale, packaging demand recovery, and the earnings normalization path. The high target of $51.00 (roughly 68% above the current price) likely assumes successful execution of the DS Smith integration, a European divestiture at an attractive multiple, and a cyclical box-demand recovery driving EPS toward or above the $3.86 consensus; the low target of $35.00 (still 15.3% above the current price) implies a more modest recovery with continued margin pressure and no value-unlocking transaction. Institutional ratings show a stable-to-positive pattern, with Citigroup, JP Morgan, Truist, Wells Fargo, and Argus all reiterating Buy/Overweight ratings through October 2026 and UBS maintaining Neutral, indicating no recent downgrades but also no fresh upgrades to catalyze a re-rating; the persistence of bullish ratings despite the price decline raises the risk of eventual target cuts if Q4 results disappoint.
Bulls vs Bears: IP Investment Factors
The bear case currently has stronger near-term evidence: the stock is 4.8% off its 52-week low, revenue is flat at -0.4% YoY, trailing FCF of $75 million does not cover a $980 million dividend, and reported margins are deeply negative. The bull case is real but forward-looking — a 39.3% analyst target upside, a PS of 0.84x versus a historical 2.1x-4.1x band, and a Q3 loss that is charge-driven rather than operational. The single most important tension is whether the $3.86 consensus EPS is achievable: if charges are truly one-time and a European sale de-levers the balance sheet, the 11.08x forward PE is a deep-value entry; if Q4 confirms structural margin pressure, the sell-side targets will be cut and the stock breaks $29.26. Until free cash flow turns positive, the discount should be treated as a warning rather than an opportunity.
Bullish
- Analyst consensus firmly bullish: 9 of 10 covering analysts rate IP a Buy with zero Sells, a recommendation mean of 1.73, and an average target of $42.30 implying 39.3% upside from $30.36. Even the low target of $35.00 sits 15.3% above the current price, meaning the entire sell-side range is above the market.
- Deep discount to own history: PS of 0.84x and P/B of 1.40x sit far below the company's own recent band (PS 2.83x in Q3 2026, 3.46x in Q4 2025, 4.08x in Q4 2024; P/B 2.29x at year-end 2024). Forward PE of 11.08x against $3.86 consensus EPS is a discount to the mid-teens typical for packaging peers.
- Q3 loss is charge-driven, not operational: The $1.126 billion Q3 net loss stems from $2.489 billion of other expenses, while gross margin held at 31.21% ($1.934 billion gross profit) and Q1 2026 was profitable at $60 million. Underlying unit economics remain intact, so the earnings bridge to $3.86 EPS is plausible if charges do not recur.
- European divestiture could unlock value: The EMEA segment contributes $1.550 billion of quarterly revenue from the DS Smith acquisition, and reports of a potential sale drove a relief rally on October 15. Proceeds could de-lever a 0.73 debt-to-equity balance sheet and support the 4.70% dividend, which currently consumes $980 million annualized against only $75 million trailing FCF.
Bearish
- Falling knife at 52-week lows: At $30.36 the stock sits just 4.8% above its 52-week low of $29.26, down 24.57% YTD and 26.83% over three months, with a -40.27% max drawdown. The 3-month decline far outpacing the 1-year decline of 14.72% shows the damage is recent and accelerating.
- Dividend not covered by cash flow: Trailing FCF is only $75 million (a ~0.4% FCF yield on a $20.8 billion market cap) against $980 million of annualized dividends, and Q3 FCF was -$267 million after $606 million of capex. The 4.70% yield with a -27.8% payout ratio is a red flag, not a cushion.
- Flat revenue, no organic growth: Q3 revenue of $6.197 billion fell 0.4% year-over-year, and the trailing four quarters ($6.006B, $5.971B, $6.004B, $6.197B) show no meaningful acceleration. The thesis rests entirely on cost execution and portfolio actions, capping multiple-expansion potential until box demand inflects.
- Reported profitability deeply negative: Trailing net margin is -14.12%, operating margin -11.33%, ROE -23.71%, and Q3 EBITDA was -$572 million, making EV/EBITDA meaningless at -314x. Earnings volatility of this magnitude (Q4 2025 EPS -$4.52, Q3 2026 -$2.13) undermines confidence in the forward earnings bridge.
IP Technical Analysis
International Paper is in a clear, sustained downtrend, with the stock down 14.72% over the past year and 24.57% year-to-date, and the current price of $30.36 sits at just 4.8% of its 52-week range of $29.26 to $50.25 (roughly $1.10 above the low). That positioning near the bottom of the range after a -40.27% max drawdown signals a falling-knife profile rather than a value entry, and the stock has given back essentially all of the mid-summer rally that carried it from $31.96 in late May to a $44.09 peak on July 28. The 52-week high of $50.25 is now 65.5% above the current price, underscoring how far sentiment has deteriorated.
Short-term momentum is decisively negative and accelerating: the stock is down 9.72% over one month and 26.83% over three months, with the 3-month decline far outpacing the 1-year decline of 14.72%, meaning the damage is recent and intensifying rather than a slow bleed. The 1-month move of -9.72% is essentially in line with the S&P 500's -9.71%, producing a relative strength of just -0.01%, but the 3-month relative strength of -16.92% and 1-year relative strength of -19.39% show severe underperformance versus the index. The most recent sessions confirm the weakness, with the stock falling from $36.64 on November 2 to $30.36 on November 20, including a -2.41% drop on the final day on volume of 8.70 million shares, suggesting distribution rather than capitulation.
Key technical support sits at the 52-week low of $29.26, only 3.6% below the current $30.36; a decisive breakdown there would likely trigger momentum-driven selling and open a new leg lower, while reclaiming the $34-$36 zone (the October consolidation area) would be the first sign of stabilization. Resistance is anchored at the $44.09 July high and the $50.25 52-week high, both far above current levels. With a beta of 0.941, the stock is slightly less volatile than the market on a historical basis, but the -40.27% max drawdown and a short ratio of 7.84 days-to-cover indicate that position sizing should account for event risk around the European asset sale and the heavy short interest that could amplify moves in either direction.
Beta
0.94
0.94x market volatility
Max Drawdown
-40.3%
Largest decline past year
52-Week Range
$29-$50
Price range past year
Annual Return
-14.7%
Cumulative gain past year
| Period | IP Return | S&P 500 |
|---|---|---|
| 1m | -9.7% | -9.2% |
| 3m | -26.8% | -9.7% |
| 6m | -3.0% | -8.1% |
| 1y | -14.7% | +4.7% |
| ytd | -24.6% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IP Fundamental Analysis
Revenue is stagnating rather than growing: the most recent quarter (Q3 2026, ended September 30) posted $6.197 billion, down 0.4% year-over-year from $6.222 billion, and the trailing four quarters of $6.006B, $5.971B, $6.004B, and $6.197B show a flat-to-modestly-improving sequential pattern with no meaningful top-line acceleration. Segment data shows Packaging Solutions North America at $3.702 billion as the core franchise, Packaging Solutions EMEA at $1.550 billion reflecting the DS Smith addition, and Global Cellulose Fibers at $643 million; the European business is the swing factor given reports of a potential sale. The flat revenue base means the investment case rests almost entirely on cost execution and portfolio actions rather than organic growth, which limits multiple expansion potential until box demand inflects.
Profitability has deteriorated sharply: Q3 2026 produced a net loss of $1.126 billion and diluted EPS of -$2.13, driven by $2.489 billion in other expenses and a -$1.113 billion operating loss, even though gross margin held at a respectable 31.21% ($1.934 billion gross profit). The prior quarter (Q2 2026) was roughly breakeven at -$12 million net income with a 27.65% gross margin, and Q1 2026 was profitable at $60 million net income on a 20.73% gross margin, so the Q3 loss is largely charge-driven rather than a collapse in underlying unit economics. Trailing net margin of -14.12% and operating margin of -11.33% reflect those charges, and the 29.53% gross margin is broadly consistent with commodity packaging peers, but the volatility of reported earnings undermines confidence in the forward earnings bridge.
Balance sheet and cash flow are the pressure point: debt-to-equity stands at 0.73 with a current ratio of 1.28, and trailing free cash flow is only $75 million against a $20.8 billion market cap, a negligible FCF yield of roughly 0.4%. Q3 operating cash flow of $339 million was swamped by $606 million of capital expenditure, producing -$267 million of free cash flow, while dividends paid of $245 million per quarter ($980 million annualized) far exceed current FCF generation. ROE of -23.71% and ROA of 1.60% confirm capital destruction on a reported basis, and the 4.70% dividend yield looks increasingly dependent on asset-sale proceeds or balance-sheet capacity rather than organic cash generation.
Quarterly Revenue
$6.2B
2026-09
Revenue YoY Growth
-0.4%
YoY Comparison
Gross Margin
31.2%
Latest Quarter
Free Cash Flow
$75000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IP Overvalued?
Because trailing net income is negative (EPS of -$0.17 and a trailing PE of -5.87x), the PE ratio is not meaningful and I have selected the price-to-sales ratio as the primary metric, supplemented by EV/Sales given negative EBITDA of -$572 million in Q3. The stock trades at a PS of 0.84x and EV/Sales of 1.06x, while the forward PE of 11.08x against consensus FY EPS of $3.86 implies the market expects a sharp earnings recovery from the current loss, a gap that reflects either significant skepticism about that recovery or substantial optionality if it materializes.
On a relative basis, the 0.84x PS and 1.06x EV/Sales are low in absolute terms and below the company's own recent history, but the comparison is distorted by the DS Smith acquisition inflating the revenue denominator; the 1.40x price-to-book is the more telling multiple, sitting near the low end of its historical band. The forward PE of 11.08x versus a sector that typically trades in the mid-teens for packaging names suggests a discount, which is arguably justified by negative trailing margins, a 0.73 debt-to-equity ratio, and execution risk on the European divestiture. The 4.70% dividend yield is well above the sector norm and is itself a valuation signal that the market doubts its sustainability given a payout ratio of -27.8%.
Historically, International Paper's PS ratio has ranged from roughly 2.1x to 4.1x over the past several years (including 2.83x in Q3 2026, 3.46x in Q4 2025, and 4.08x in Q4 2024), so the current 0.84x is far below its own historical band and near multi-year lows. Price-to-book of 1.40x compares with 2.29x at year-end 2024 and 1.97x in Q3 2024, again near the bottom of the range. This compression could represent a genuine value opportunity if earnings normalize toward the $3.86 consensus, but it equally reflects fundamental deterioration and balance-sheet stress, so the discount should be treated as a warning until free cash flow turns positive.
PE
-5.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~84x
vs. Industry Avg
25.2x
Industry PE ~25.2x*
EV/EBITDA
-314.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute. Trailing free cash flow of just $75 million against $980 million of annualized dividends ($245 million per quarter) means the 4.70% yield is funded by balance-sheet capacity or asset-sale proceeds, not organic cash generation, and Q3 FCF was -$267 million after $606 million of capex. Debt-to-equity of 0.73 with a current ratio of 1.28 leaves limited cushion, while earnings volatility is extreme — Q4 2025 EPS of -$4.52 and Q3 2026 EPS of -$2.13, with Q3 EBITDA of -$572 million — and revenue is concentrated in North American Packaging Solutions ($3.702 billion of $6.197 billion quarterly revenue) with flat -0.4% YoY growth. ROE of -23.71% confirms capital destruction on a reported basis.
Market and competitive risks center on valuation compression and cyclicality. The stock trades at 0.84x PS and 1.40x P/B, far below its historical 2.1x-4.1x PS band, which could reflect either opportunity or justified deterioration; if Q4 disappoints, the 9 Buy ratings and $42.30 average target are vulnerable to cuts, removing the main support for the price. Beta of 0.941 offers only modest defensive characteristics, and relative strength of -16.92% over three months and -19.39% over one year shows severe underperformance versus the S&P 500. News flow highlights that the October 15 rally was a relief bounce on a potential European sale while the core North American business remains weak, and the $360 million NORPAC acquisition adds integration risk into a soft box-demand cycle.
In a worst-case scenario, Q4 results confirm that Q3 charges were not fully one-time, the European sale stalls or prices below expectations, and box demand fails to recover, forcing a dividend cut and analyst downgrades. The stock would likely break the 52-week low of $29.26 and extend toward the -40.27% max drawdown trajectory, implying a decline of roughly -3.6% to the 52-week low and potentially -15% to -25% from $30.36 in a prolonged de-rating. With a 7.84-day short ratio, such a break could accelerate selling as momentum funds exit, and the absence of any Sell-rated analyst means downgrades would arrive as a fresh, unanticipated shock.
FAQ
The most severe risk is financial: trailing free cash flow of just $75 million against $980 million of annualized dividends and -$267 million of Q3 FCF means the 4.70% yield depends on balance-sheet capacity or asset-sale proceeds, and a dividend cut would likely trigger analyst downgrades from a base of zero Sells. Second is earnings-quality risk: Q3 produced a $1.126 billion net loss on $2.489 billion of other expenses, and the pattern of large charges (Q4 2025 EPS -$4.52, Q3 2026 EPS -$2.13) raises the possibility that some costs are recurring rather than one-time, which would invalidate the $3.86 EPS bridge. Third is execution and portfolio risk: the European divestiture could stall or price below expectations, leaving a 0.73 debt-to-equity balance sheet levered with negative FCF, while the $360 million NORPAC acquisition adds integration risk into a soft box-demand cycle. Fourth is market and technical risk: beta of 0.941 offers only modest defensiveness, relative strength is -19.39% over one year versus the S&P 500, and a break of the $29.26 low with a 7.84-day short ratio could accelerate momentum selling toward the -40.27% max drawdown trajectory.
The 12-month outlook splits into three scenarios: a 50% base case targeting $33.00-$42.30 in which charges do not fully recur but margins stay pressured, revenue holds near $6.0-6.2 billion per quarter, and the stock grinds back toward the $35.00 low target without a full re-rating; a 25% bull case targeting $42.30-$51.00 in which Q4 confirms one-time charges, the European business sells at an attractive multiple, and box demand inflects, driving EPS toward or above $3.86 and a re-rating from 11.08x forward PE; and a 25% bear case targeting $25.00-$29.26 in which structural margin pressure persists, the European sale stalls, and a dividend cut forces downgrades and a break below the 52-week low. The base case is most likely because it requires only that the Q3 charges prove non-recurring without demanding a demand recovery or a successful divestiture. The key assumption behind it is that gross margin holds near the 29.5-31.2% range and free cash flow turns modestly positive, keeping the dividend intact while the stock trades in a wide $33-$42 range.
On most measures IP screens as undervalued relative to its own history: PS of 0.84x versus a recent band of roughly 2.1x-4.1x (including 2.83x in Q3 2026 and 4.08x in Q4 2024), P/B of 1.40x versus 2.29x at year-end 2024, and forward PE of 11.08x versus mid-teens typical for packaging peers. However, trailing PE of -5.87x and EV/EBITDA of -314x are meaningless because trailing net income is negative (EPS -$0.17) and Q3 EBITDA was -$572 million, so the valuation must be judged on normalized earnings. The market is effectively pricing skepticism that the $3.86 consensus EPS is achievable — the 11.08x forward multiple embeds a sharp recovery from the current loss, and the 4.70% dividend yield signals doubt about sustainability given a -27.8% payout ratio. The verdict is fairly valued to modestly cheap on normalized earnings but expensive on trailing cash flow; the discount is arguably deserved until free cash flow turns positive, at which point the multiple could re-rate toward peer levels.
From a pure risk/reward standpoint, IP offers an asymmetric setup: the average analyst target of $42.30 implies 39.3% upside, and even the lowest target of $35.00 sits 15.3% above the $30.36 price, while the downside to the 52-week low of $29.26 is only about 3.6%. That asymmetry is offset by the fact that trailing free cash flow of $75 million cannot cover $980 million of annualized dividends, revenue is flat at -0.4% YoY, and the stock is down 24.57% YTD with a -40.27% max drawdown. The Q3 net loss of $1.126 billion was driven by $2.489 billion of other expenses while gross margin held at 31.21%, so the bull case hinges on those charges being truly one-time. It is a reasonable buy only for patient, risk-tolerant value investors who size positions for volatility and can wait for confirmation of positive free cash flow or a European asset sale; it is not a good buy for income-dependent investors given the -27.8% payout ratio, nor for short-term traders given the falling-knife technicals.
IP is better suited to a long-term holding period of at least 12-24 months than to short-term trading. The thesis depends on an earnings-normalization bridge to $3.86 consensus EPS and a potential European divestiture, both of which are multi-quarter events, and the stock's -40.27% max drawdown with a 7.84-day short ratio makes near-term price action highly event-driven and unpredictable. Beta of 0.941 is only slightly below the market, so it offers limited defensive ballast, and the 4.70% dividend yield provides some carry but is not currently covered by $75 million of trailing FCF, meaning income investors should wait for confirmation of cash generation. The deep-value entry at 0.84x PS and 1.40x P/B rewards patience if the turnaround materializes, but the flat -0.4% revenue growth and negative trailing margins mean there is no momentum case for a short-term trade. A concrete minimum holding period of 18 months allows time for two to three earnings cycles to confirm whether Q3 charges were truly one-time and whether the European sale closes.

